Reply to: "Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study"

Affiliations

¹ AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Univ Paris-Sud, UMR-S 1193, Université Paris-Saclay Villejuif, DHU Hepatinov, France.
² Département d'innovation thérapeutique et d'Essais Précoces (DITEP), Institut Gustave-Roussy, Université Paris Saclay, Villejuif, France.
³ AP-HP Hôpital Bicêtre, Department of Pathology, Le Kremlin-Bicêtre, France; Univ Paris-Sud, UMR-S 1193, Université Paris-Saclay, France.
⁴ APHP Hôpital Bicêtre, Service de Médecine Interne et Immunologie Clinique, Université Paris Sud, CEA, DSV/iMETI, Division of Immunovirology, IDMIT, INSERM, U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin Bicêtre, France.
⁵ Dermatology Unit, Department of Medical Oncology, Gustave Roussy, Paris Sud University, Villejuif, France.
⁶ AP-HP Hôpital Bicêtre, Department of Pathology, Le Kremlin-Bicêtre, France.
⁷ AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Univ Paris-Sud, UMR-S 1193, Université Paris-Saclay Villejuif, DHU Hepatinov, France. Electronic address: didier.samuel@aphp.fr.

Comment

Eleonora De Martin et al. J Hepatol. 2018 Dec.

. 2018 Dec;69(6):1397-1398.

doi: 10.1016/j.jhep.2018.09.006. Epub 2018 Oct 5.

¹ AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Univ Paris-Sud, UMR-S 1193, Université Paris-Saclay Villejuif, DHU Hepatinov, France.
² Département d'innovation thérapeutique et d'Essais Précoces (DITEP), Institut Gustave-Roussy, Université Paris Saclay, Villejuif, France.
³ AP-HP Hôpital Bicêtre, Department of Pathology, Le Kremlin-Bicêtre, France; Univ Paris-Sud, UMR-S 1193, Université Paris-Saclay, France.
⁴ APHP Hôpital Bicêtre, Service de Médecine Interne et Immunologie Clinique, Université Paris Sud, CEA, DSV/iMETI, Division of Immunovirology, IDMIT, INSERM, U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin Bicêtre, France.
⁵ Dermatology Unit, Department of Medical Oncology, Gustave Roussy, Paris Sud University, Villejuif, France.
⁶ AP-HP Hôpital Bicêtre, Department of Pathology, Le Kremlin-Bicêtre, France.
⁷ AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Univ Paris-Sud, UMR-S 1193, Université Paris-Saclay Villejuif, DHU Hepatinov, France. Electronic address: didier.samuel@aphp.fr.

No abstract available

Comment on

Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A, Laghouati S, Robert C, Marabelle A, Guettier C, Samuel D. De Martin E, et al. J Hepatol. 2018 Jun;68(6):1181-1190. doi: 10.1016/j.jhep.2018.01.033. Epub 2018 Feb 8. J Hepatol. 2018. PMID: 29427729
Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study.
Parlati L, Vallet-Pichard A, Batista R, Hernvann A, Sogni P, Pol S, Mallet V; CERTIM group. Parlati L, et al. J Hepatol. 2018 Dec;69(6):1396-1397. doi: 10.1016/j.jhep.2018.08.014. Epub 2018 Oct 3. J Hepatol. 2018. PMID: 30292476 No abstract available.